Noteworth Secures $5 Million in Funding

July 15, 2020

Noteworth, a first-of-its-kind Digital Healthcare platform for modernizing Digital Medicine delivery operations, announced a $5 million oversubscribed seed funding round led by Laconia Capital Group with participation from Draper Associates, Frontier Ventures, Techstars Ventures, Wavemaker360, Springtide Capital and others.

Noteworth states the funding will be used to expand operations of their digital medical technology and make strategic hires necessary to meet the growing demand from healthcare providers and patients.

With this new investment, the company will continue to build upon the delivery of Noteworth’s first-of-its-kind Digital Healthcare platform. The platform provides a number of beneficial capabilities including expanded access to care in order to eliminate the barriers to care by putting health services into the patient’s hands. One of the main goals for the company is working to extend patient engagement by providing clinicians with the tools to communicate directly with patients through video, chat, and push notifications. The Noteworth platform works to help reduce costs by decreasing readmissions and the use of high-cost services with timely interventions. In addition, Noteworth will help clinicians obtain new reimbursements to generate additional income for new streams of revenue.

“The positive response and support of our strategic investors reflect a shared belief that digital medicine is the future of healthcare delivery,” said Justin Williams, Co-founder, and CEO of Noteworth. “With this new round of funding, Noteworth will continue to establish our ability to quickly and efficiently help healthcare providers launch our digital medicine technology platform offering to better serve their patient populations remotely.”

“Noteworth is a rising star in the field of digital medicine,” said David Arcara, Managing Partner of Laconia Capital Group. “Their ability to provide unprecedented healthcare data collection, assessment and proactive intervention across all current digital healthcare information silos, consistent with our investment thesis focused on digital workflow transformation, is what prompted our investment in this critical technology that is modernizing healthcare delivery. Laconia invests in companies that pioneer the digital transformation from legacy software and manual workflow processes into 21st century cloud-based platforms.”

“At Draper Associates, we are looking for companies that can become fundamental to an industry,” said Tim Draper, Founder and Managing Partner of Draper Associates. “Noteworth is an easy to use system that monitors the patient’s progress, improves profitability for the caregiver and derives insightful data for health care generally. We expect every doctor and every patient to be a part of this easy-to-use communications tool.”

SourceNoteworth

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version